Introduction
France is an important pharmaceutical market within the European Union (EU), but obtaining marketing authorisation requires more than preparing a technically complete dossier. Companies must select the appropriate European or national procedure, meet applicable documentation requirements and plan for French-specific obligations before launch.
Understanding France drug registration requirements early helps pharmaceutical companies align their regulatory strategies services with their intended markets, avoid preventable submission gaps and plan for post-authorisation compliance. The right approach depends on the medicine, its existing authorisations and whether the company intends to enter France alone or pursue a wider European launch. A clear strategy for France pharmaceutical registration also helps companies coordinate regulatory requirements with their intended European market-entry plans.
Understanding France's Pharmaceutical Regulatory Framework
France operates within the EU pharmaceutical regulatory framework, with the Agence nationale de sécurité du médicament et des produits de santé (ANSM) serving as its national medicines authority.
ANSM assesses and authorises medicines through applicable national and European procedures, oversees medicine safety and quality, and manages relevant national regulatory responsibilities. The European Medicines Agency (EMA) coordinates scientific evaluation for medicines assessed through the centralised procedure, while the European Commission grants the resulting EU-wide marketing authorisation.
A centralised authorisation is valid across the EU, whereas national, decentralised and mutual recognition procedures result in authorisations applicable to the participating countries.
France Drug Registration Requirements
The core requirements depend on the selected procedure and product category. Applications generally need to demonstrate that the medicine meets applicable standards for quality, safety and efficacy.
Understanding ANSM drug registration requirements alongside the applicable EU rules helps applicants identify the documentation, quality standards and procedural obligations relevant to their submission.
Key requirements include:
- A complete marketing authorisation dossier in the applicable Common Technical Document (CTD) structure.
- Pharmaceutical quality and manufacturing information, including relevant Good Manufacturing Practice (GMP) compliance.
- Non-clinical and clinical evidence appropriate to the product and application type.
- Proposed product information, including the Summary of Product Characteristics (SmPC), package leaflet and labelling.
- Pharmacovigilance documentation and a risk management plan, where applicable.
- An eligible applicant and marketing authorisation holder (MAH) arrangement that meets applicable EU legal requirements.
Which Marketing Authorisation Pathway Applies in France?
The appropriate marketing authorisation pathway depends on the medicine’s eligibility, existing authorisation status and intended markets. The four main routes are not interchangeable, and the centralised procedure is mandatory for certain categories of medicines.
- National procedure: May be appropriate when authorisation is sought in France alone and the medicine is eligible for a national route.
- Decentralised procedure (DCP): Applies when a medicine has not yet been authorised in the EU and the applicant seeks authorisation simultaneously in France and other participating Member States.
- Mutual recognition procedure (MRP): Applies when a medicine already holds a national marketing authorisation in one EU Member State and the applicant seeks recognition in additional Member States.
- Centralised procedure: Results in a single EU-wide marketing authorisation following EMA scientific assessment and a European Commission decision. It is mandatory for specified categories of medicines and may be available for other eligible products.
Before selecting a route, companies should confirm the product’s legal classification, eligibility, existing authorisation status and target markets. This helps establish a suitable regulatory strategy and avoid planning around a procedure that cannot be used for the product.
The EMA overview of medicine authorisation explains the main procedures and their scope.
Step-by-Step Drug Registration Process in France
A structured approach to Drug registration in France helps companies manage the regulatory process from initial planning through marketing authorisation and preparation for post-authorisation compliance.
The France drug approval process varies according to the product’s eligibility, the selected authorisation pathway and the scope of the proposed application.
- Confirm product classification and eligibility. Establish the applicable legal framework, product category and available authorisation pathways.
- Define the target markets. Determine whether the objective is a France-only launch or authorisation across multiple European countries.
- Conduct a regulatory gap assessment. Review existing quality, non-clinical, clinical and product information against the requirements of the intended application.
- Prepare and validate the dossier. Compile the relevant CTD modules, confirm consistency across documents and complete technical and administrative quality checks.
- Submit through the applicable procedure. Follow the relevant submission requirements and address validation issues before or during assessment as required.
- Respond to regulatory questions. Coordinate scientific and technical responses, ensuring that any commitments or changes remain consistent across the dossier.
- Prepare for launch and ongoing compliance. Plan product information implementation, pharmacovigilance, supply responsibilities and any separate pricing or reimbursement procedures.
Timelines vary according to the procedure, application type, validation outcome and assessment questions. Sponsors should use the applicable procedural timetable rather than assume a single approval timeline for every medicine.
Documents Required for French Marketing Authorisation
The documentation package depends on the product and pathway, but a typical application may include:
- Administrative and application forms.
- Quality documentation covering the active substance, finished product, manufacturing and controls.
- Non-clinical and clinical study reports, where required.
- SmPC, package leaflet and proposed labelling.
- Pharmacovigilance system information and the risk management plan, as applicable.
- Supporting certificates, declarations and evidence required for the specific application.
For generic and other abridged applications, the evidence package may differ from that required for a new active substance. Companies should establish the precise documentation requirements before compiling the submission rather than relying on a generic checklist.
French-language product information: For medicines marketed in France, the Summary of Product Characteristics (SmPC), package leaflet and labelling generally need to be available in French, subject to applicable EU and national rules and any permitted exceptions. Companies should plan translation, terminology consistency and quality review early to ensure that the product information remains aligned with the approved dossier.
ANSM Requirements After Marketing Authorisation
Obtaining authorisation is not the end of regulatory responsibility. Marketing authorisation holders must maintain compliance throughout the medicine’s lifecycle. Depending on the product and authorisation route, ongoing responsibilities include pharmacovigilance and safety reporting, risk management, submission of applicable variations, renewals where required, and keeping product information up to date.
Companies should also monitor relevant regulatory changes and maintain appropriate arrangements for manufacturing quality, distribution and regulatory communication. France-specific obligations must be assessed alongside applicable EU requirements.
Common Challenges in France Drug Registration
Several issues can complicate registration and launch planning:
- Incorrect pathway selection: Choosing a procedure that does not match product eligibility or commercial objectives.
- Dossier inconsistencies: Differences between quality data, clinical evidence and proposed product information.
- Incomplete documentation: Missing administrative elements or supporting evidence that delay validation or assessment.
- Labelling and language gaps: Failure to prepare product information in the required language and format.
- Post-authorisation planning gaps: Underestimating ongoing pharmacovigilance, variation management or other lifecycle obligations.
Identifying these issues before submission can reduce avoidable rework and support a more predictable regulatory process.
How Foreign Companies Can Prepare for Market Entry in France
Foreign pharmaceutical companies should begin by defining their intended launch scope and confirming whether an EU-wide or country-specific pathway is appropriate. They should assess applicant and MAH eligibility, identify the documentation and language requirements, review manufacturing and quality compliance, and establish responsibilities for regulatory communication and pharmacovigilance.
Regulatory approval should also be distinguished from commercial access. For medicines seeking reimbursement in France, additional health technology assessment and pricing processes may apply. The Haute Autorité de Santé (HAS) evaluates the clinical benefit and related considerations, while pricing and reimbursement decisions involve the relevant French bodies and procedures. Planning these activities alongside the authorisation strategy helps companies avoid treating marketing authorisation as the only milestone before launch.
How Regulatory Affairs Consulting Can Support France Market Entry
DDReg supports pharmaceutical companies with regulatory strategy, dossier preparation and publishing, eCTD submission planning, regulatory intelligence and post-authorisation lifecycle activities.
For companies entering France, this support can help clarify the applicable pathway, assess dossier readiness, identify France-specific requirements and coordinate regulatory activities across the EU and national framework. The scope can be tailored to the product, target markets and stage of development.
The aim is to establish a clear regulatory plan from initial pathway assessment through submission and ongoing compliance, while helping teams identify gaps before they affect launch plans.
Conclusion
Successful Drug registration in France requires more than preparing a compliant dossier. Companies must confirm the appropriate marketing authorisation pathway, assess dossier readiness, align product information with applicable French-language requirements and plan for post-authorisation obligations from the outset. These decisions help reduce avoidable regulatory delays and support a more realistic market-entry timeline.
For foreign pharmaceutical companies, early regulatory planning can clarify the requirements, responsibilities and resources needed to enter the French market. With a well-defined strategy and appropriate regulatory support, companies can navigate France drug registration requirements more efficiently and build a stronger foundation for sustainable market access.
Frequently Asked Questions
No. A centrally authorised medicine can be marketed throughout the EU under its single authorisation. Medicines authorised through national, DCP or MRP routes are covered in the countries for which the relevant authorisation has been granted.
Yes, provided the applicant and MAH arrangements satisfy the applicable legal requirements. For EU marketing authorisations, the MAH must generally be established within the European Economic Area (EEA). Companies should confirm the requirements applicable to their chosen procedure.
No. Marketing authorisation and reimbursement are separate processes. Additional assessment and pricing steps may be required for medicines seeking reimbursement under the French healthcare system.
The timeline depends on the authorisation procedure, application type, dossier completeness and regulatory questions raised during assessment. The applicable procedural timetable should be confirmed for the specific application.